Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL6210360 | 0.84 | MEN1 (0.53) | MEN1LMNAKMT2ATDP1ALDH1A1 | |
| Tromethamine SCHEMBL7567125 | 0.83 | LMNA (0.67) | MEN1LMNAKMT2ATDP1ALDH1A1 | |
| Tromethamine SCHEMBL8530728 | 0.82 | MEN1 (0.36) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL1155666 | 0.79 | MEN1 (0.53) | MEN1LMNAKMT2ATDP1 | |
| Tromethamine SCHEMBL9363390 | 0.78 | MEN1 (0.59) | MEN1LMNAKMT2ATDP1 | |
| Tromethamine SCHEMBL8334055 | 0.78 | LMNA (0.59) | MEN1LMNAKMT2ATDP1ALDH1A1 | |
| Tromethamine SCHEMBL4737664 | 0.76 | MEN1 (0.56) | MEN1LMNAKMT2ATDP1 | |
| Tromethamine SCHEMBL9547767 | 0.76 | MEN1 (0.56) | MEN1LMNAKMT2ATDP1ALDH1A1 | |
| Tromethamine SCHEMBL4735605 | 0.76 | MEN1 (0.56) | MEN1LMNAKMT2ATDP1 | |
| Tromethamine SCHEMBL9443897 | 0.75 | MEN1 (0.62) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668161-B1 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8754111-B2 | Method and substances for preparation of N-substituted pyridinium compounds | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2668161-A1 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | Roche Diagniostics GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303768-A1 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101095-A1 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303768-A1 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | PNMT, HNMT, CHRM5 | MEN1 661/4885LMNA 829/4885KMT2A 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.